Bioneer Corporation (064550.KQ) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · South Korea · ISIN KR7064550007

Price
6,810.00 KRW
Market cap
175.77 bn KRW
P/E (2025)
–
P/S (2025)
0.53
Dividend yield
0.00 %
Net margin
-0.85 %
Return on equity (ROE)
-1.24 %
Return on assets (ROA)
-0.76 %

Bioneer Corporation financials

Fiscal year20242025
Revenue293.98 bn KRW330.11 bn KRW
Gross profit219.93 bn KRW257.23 bn KRW
Operating income-13.57 bn KRW14.14 bn KRW
EBIT-11.91 bn KRW14.52 bn KRW
Net income-20.58 bn KRW-2.81 bn KRW
Diluted EPS – continuing operations-797.52 KRW-108.99 KRW

Full history since 2011, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Bioneer Corporation

Bioneer Corporation engages in the biotechnology research products, molecular diagnosis, drugs, and probiotics businesses in South Korea. The company offers PCR and RT-PCR, real-time PCR, RNAi, chemicals, plastic consumables, and buffer solutions; and sample preparation, protein synthesis and purification, gene cloning, fluorescence dye and quencher, electrophoresis, genome-wide functional analysis, and magnetic separation services, as well as instruments for conventional PCR, real-time PCR, sample preparation, protein synthesis, centrifuge and vortex mixer, electrophoresis, spectrophotometer, and microbial culture. It also provides molecular diagnosis, including MDx technologies, human diagnostics kits, MDx extraction kits, and instruments; and products for animal diseases and nano-bio products. The company was founded in 1992 and is headquartered in Daejeon, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.